Andrew Mackie, Non-Executive Director

Andrew Mackie is Head of Life Sciences at IPG, joining in 2005 to develop portfolio companies and work with university partners on identifying new investment opportunities. Andrew has held positions in pre-clinical research, clinical development and business development for multinational pharmaceutical (Novartis, Sanofi-Aventis) and service companies (MDS). Andrew joined the UK biotech sector at Antisoma prior to its IPO, initially to establish the clinical department. Later he managed Antisoma's strategic alliance with F Hoffman-La Roche and participated in the in-licensing of new drug leads through partnerships and acquisitions. Andrew holds a BSc in biochemistry from Queen's Canada, an LLB from the University of London and an MBA from the London Business School where he graduated with distinction.